They work as GLP-1 receptor agonists that mimic the feeling of fullness or satiety
In November 2024, the Biden administration proposed expanding Medicare and Medicaid coverage for anti- obesity drugs, potentially extending coverage to an estimated 3.4 million Americans insured by Medicare and an additional four million by Medicaid
Our Approach at Family Health Care At Family Health Care, your safety and well-being come first
Eating smaller, more frequent meals rather than large portions reduces gastric distress
Third, the TRIUMPH-4 population (obesity plus knee OA) is slightly different from the STEP-1 and SURMOUNT-1 populations (general obesity), so the definitive head-to-head comparison waits for TRIUMPH-1
Of the participants with both EHR and survey data, 125 self-reported using semaglutide, of whom 97.6% had a corroborating EHR record